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Abstract
© Schattauer 2017. The optimal duration and cancer risks of antiplatelet therapy following
percutaneous  coronary  intervention  (PCI)  are  unclear.  We  compared  cancer  and  all-cause
mortality after dual antiplatelet therapy (DAPT) for the combination of clopidogrel and aspirin
(ASA) versus ASA alone over 18 months follow-up in event-free patients at 12 months DAPT
from the Health Insurance Review and Assessment (HIRA) dataset via the Korean Outcomes
Registry Evaluating Antithrombotics (KOREA). We selected PCI patients who were event free for
12 months and maintained a consistent antiplatelet regimen for 18 more months. The primary
endpoints were any cancer and all-cause mortality at 30 months follow-up after PCI.  From
320,351 screened post-PCI patient HIRA records, we excluded 294,413 and qualified 25,938,
constituting DAPT (n=10,992)  and ASA (n=14,946)  groups.  The Propensity  Score Matching
(PSM), and Inverse Probability of Treatment Weighting (IPTW) revealed no significant differences
in background demographics and clinical characteristics for DAPT versus ASA patients. At 30-
months post-PCI, after massive ( > 91 %) exclusions, cancer risk was higher for continuous
DAPT  [455  (4.15  %)  vs  606  (4.04  %);  HR=1.221;  95  %CI:  1.061-1.405;  p=0.005],  which
remained significant by PSM (p=0.006) or IPTW (p=0.007), while all-cause mortality was similar
[136 (1.24 %) vs  192 (1.28 %) HR=0.999;  95 %CI:  0.736-1.135;  p=0.993]  .  This  analysis
suggests a potential mild excess cancer risk, but no mortality benefit in Korean post-PCI patients
treated with DAPT for an additional 18 months beyond conventional 12 months DAPT. These
data are not supporting continuing DAPT for more than one year in East Asians. Analysing
cancer types and assessing potential cancer association with bleeding are warranted.
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